"With two large campuses in Berlin, New Jersey, and Marlton, New Jersey, (both just twenty minutes from Philadelphia), Hassman Research Institute (HRI) is a leading clinical research organization that conducts studies in a wide variety of therapeutic areas. HRI’s highly trained and experienced staff, including four board certified clinical investigators, is dedicated to maintaining the highest standard of quality results in the trials they conduct. On the HRI campus there are fourteen private practices led by physicians that serve as sub-investigators."

During the past decade, Hassman Research Institute conducted 149 clinical trials. In the 10-year time frame, 149 clinical trials started and 60 clinical trials were completed, i.e. on average, 40.3% percent of trials that started reached the finish line to date. In the past 5 years, 86 clinical trials started and 55 clinical trials were completed. i.e. 64% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hassman Research Institute" #1 sponsor was "Pfizer" with 7 trials, followed by "Boehringer Ingelheim" with 6 trials sponsored, "Eli Lilly and Company" with 6 trials sponsored, "Indivior Inc." with 6 trials sponsored and "Otsuka Pharmaceutical Development & Commercialization, Inc." with 6 trials sponsored. Other sponsors include 118 different institutions and companies that sponsored additional 84 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hassman Research Institute" #1 collaborator was "H. Lundbeck A/S" with 5 trials as a collaborator, "Alkermes, Inc." with 2 trials as a collaborator, "Anavex Life Sciences Corp." with 2 trials as a collaborator, "Apex Innovative Sciences" with 2 trials as a collaborator and "Astellas Pharma Inc" with 2 trials as a collaborator. Other collaborators include 34 different institutions and companies that were collaborators in the rest 33 trials.

According to Clinical.Site data, the most researched conditions in "Hassman Research Institute" are "Schizophrenia" (29 trials), "Depressive Disorder, Major" (12 trials), "Major Depressive Disorder" (6 trials), "Healthy" (5 trials) and "Attention Deficit Hyperactivity Disorder" (4 trials). Many other conditions were trialed in "Hassman Research Institute" in a lesser frequency.

Most popular intervention types in "Hassman Research Institute" are "Drug" (144 trials), "Other" (17 trials), "Biological" (5 trials), "Device" (3 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (72 trials), "placebo" (6 trials), "Rapastinel" (5 trials), "Xanomeline and Trospium Chloride Capsules" (5 trials) and "Rimegepant" (4 trials). Other intervention names were less common.

The vast majority of trials in "Hassman Research Institute" are 147 trials for "All" genders, 5 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 33 active trials in "Hassman Research Institute". 1 are not yet recruiting, 21 are recruiting, 10 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 102 completed trials in Hassman Research Institute, 1 suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Hassman Research Institute, 37 "Phase 1" clinical trials were conducted, 44 "Phase 2" clinical trials and 66 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 2 trials that are defined as “Not Applicable".